CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 191 enrolled
Drug / intervention
Lurasidonedrug
Likely dose
Lurasidone 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01566162
NCT01566162Phase 3Completed
CompareCT.gov

A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia

Sumitomo Pharma America, Inc.·interventional·Posted Mar 29, 2012·Updated Apr 9, 2019

In Brief

A Phase 3 clinical trial evaluating Lurasidone for Schizophrenia. Completed, enrolled 191 participants across 63 sites in 7 countries.

Detailed Summary

This is a 12-week, multi-center, open-label extension study designed to evaluate the longer-term safety, tolerability and effectiveness of lurasidone for the treatment of subjects with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesFrance, Italy, Russia, Serbia, Slovakia, South Africa, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 29, 2012
Enrollment StartApr 1, 2012
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.3 years ago

Interventions

Lurasidonedrug

Lurasidone 40-80 mg taken orally taken once daily